louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00724763: The Effect of Acupuncture on Blood Pressure and Heart Rate Variability (HRV)
Official title: The Effect of Acupuncture on Blood Pressure and HRV
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Hypertension
Keywords: acupuncture, high blood pressure, HRV
Lead sponsor: Logan College of Chiropractic
Sponsor class: OTHER
First posted: 2008-07-30
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This research is designed to study the effects of needle acupuncture on blood pressure and HRV by stimulating certain acupuncture points and meridians.

Detailed description: Outcome measurements include blood pressure and heart rate variability.

Eligibility criteria: Inclusion Criteria:

* Male or female suffering from mild hypertension (systolic BP between 130-165 mmHg, diastolic BP between 90-120 mmHg).

Exclusion Criteria:

* Individuals with heart, kidney, thyroid disorders, diabetes, chronic disease or illness, neurological diseases, skin or bleeding disorders,
* Currently taking prescription or OTC medications and/or herb/supplements that effect BP or autonomic tone will not be recruited into the study.
* In addition, individuals who have a pacemaker and/or are pregnant will not be recruited in the study. A health history questionnaire was used to screen subjects.

Primary outcomes:
measure: Blood pressure and HRV
timeFrame: five weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chesterfield
country: United States
facility: Logan University
state: Missouri
Study officials:
References:
Clinical trial NCT03823963: Study on Pressure Ulcers Prevention With Mepilex® Border Sacrum Dressing in Scheduled Cardiovascular Surgery
Official title: A Monocentric, Comparative and Randomized Study on Pressure Ulcers Prevention With Mepilex® Border Sacrum Dressing in Scheduled Cardiovascular Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Pressure Ulcers
Prevention
Skin Ulcer
Ulcer
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
Collaborators: name: Molnlycke Health Care AB
First posted: 2019-01-31
Enrollment: 478
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study is a randomised controlled trial of patients admitted for a scheduled cardiac surgery at the Clermont-Ferrand hospital.

Patients meeting the study inclusion criteria will be allocated to either the control group that will receive pressure ulcer prevention standard care or the intervention group that will receive pressure ulcer prevention standard care plus have a Mepilex® Border dressing applied to their sacrum.

Detailed description: The main objective of this research is to evaluate the impact of Mepilex Border® dressing applied in addition to standard pressure ulcer prevention protocol, in a French hospital setting, in at-risk patients in a cardiovascular surgery unit with full hospitalisation including block operation and ICU.

Hypothesis: Patients treated with Mepilex® Border dressings will have a lower incidence rate of sacral pressure ulcer development than patients receiving standard care.

Eligibility criteria: Inclusion Criteria:

* Subject over 18 years of age,
* Subject programmed to benefit from cardiac surgery with sternotomy,
* Subject capable and willing to comply with the protocol and willing to give his written consent,
* Subject affiliated to a social security system

Exclusion Criteria:

* Subject with a skin lesion in the sacral area upon admission,
* Subject admitted for emergency cardiovascular surgery (unscheduled subject),
* Subject admitted for heart transplant surgery,
* Subject participating in another clinical study or in a period of exclusion from a study previous,
* Subject with a linguistic or psychological disability to sign informed consent,
* Subject refusing to give written consent,
* Subject deprived of liberty by administrative or judicial decision, under guardianship or curatorship.

Primary outcomes:
measure: Pressure ulcer incidence
timeFrame: 0-20 days
Secondary outcomes:
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: Chu Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Franck HENTZ
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01490463: Brain Lesions Following Endovascular and Surgical Treatment of Unruptured Intracranial Aneurysms
Official title: Brain Lesions Following Endovascular and Surgical Treatment of Unruptured Intracranial Aneurysms: Incidence and Influence on Clinical Outcome in a Prospective Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Unruptured Intracranial Aneurysms
Keywords: Treatment of
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
Collaborators: name: Department of Neurosurgery, Goethe-University Frankfurt am Main
name: Institute of Neuroradiology, Goethe-University Frankfurt am Main
First posted: 2011-12-13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with unruptured intracranial aneurysm undergoing endovascular or surgical treatment

Brief summary: The purpose of this study is to determine the incidence and impact of brain lesions in MRI after coiling and clipping of unruptured intracranial aneurysms on clinical and neurological outcome of patients.

Detailed description: Silent ischemic lesions after treatment of unruptured intracranial aneurysm (UIA) might alter patients' clinical and neurological outcome. Furthermore silent brain lesions are not well documented after endovascular and surgical treatment of unruptured intracranial aneurysms. Therefore, the investigators investigate the incidence and influence of treatment-related ischemic lesions in magnetic resonance / diffusion-weighted-imaging after endovascular and surgical treatment of UIA.

Eligibility criteria: Inclusion Criteria:

* diagnosis and treatment of unruptured intracranial aneurysm
* age ≥ 18 yrs
* written informed consent by patients prior to study participation
* willingness to participate in follow-up

Exclusion Criteria:

* ruptured intracranial aneurysm
* contraindication for MRI
* Participation in an intervention-/AMG-study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Frankfurt am Main
country: Germany
facility: Department of Neurosurgery, Goethe-University
state: Hessen
Study officials:
References:
citation: Platz J, Wagner M, Guresir E, You SJ, Konczalla J, de Rochemont RD, Berkefeld J, Seifert V. Early diffusion-weighted MRI lesions after treatment of unruptured intracranial aneurysms: a prospective study. J Neurosurg. 2017 Apr;126(4):1070-1078. doi: 10.3171/2016.2.JNS152456. Epub 2016 May 20.
Clinical trial NCT00243763: TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
Official title: Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Multiple Myeloma
Keywords: Refractory Multiple Myeloma or
Relapsed Multiple Myeloma
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-10-25
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of multiple myeloma
* Evidence of relapsed or refractory disease

Exclusion Criteria:

* Intracranial disease or epidural disease
* Clinically significant cardiac disease
* Diabetes mellitus

Primary outcomes:
measure: Maximum tolerated dose
measure: Dose limiting toxicity
measure: Safety profile
Secondary outcomes:
measure: Evaluation of pharmacokinetics and pharmacodynamics
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic - Arizona
state: Arizona
city: Tampa
country: United States
facility: H. Lee Moffitt Cancer Center and Research Institute
state: Florida
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Rochester
country: United States
facility: Mayo Clinic - Minnesota
state: Minnesota
Study officials:
affiliation: Novartis
name: Novartis
role: STUDY_CHAIR
References:
citation: Wang X, Kay A, Anak O, Angevin E, Escudier B, Zhou W, Feng Y, Dugan M, Schran H. Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib. J Clin Pharmacol. 2013 Jan;53(1):14-20. doi: 10.1177/0091270011433330. Epub 2013 Jan 24.
Clinical trial NCT03290586: Fusion Rates and Cost Analysis of Patients Undergoing 1st Metatarsal Phalangeal Joint Arthrodesis
Official title: Fusion Rates and Cost Analysis of Patients Undergoing 1st Metatarsal Phalangeal Joint Arthrodesis; the Evaluation of a Novel, Single Use Sterile, Disposable Delivery System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: First Metatarsophalangeal Joint Arthritis
Lead sponsor: JEM Research Institute
Sponsor class: INDUSTRY
Collaborators: name: Flower Orthopedics
First posted: 2017-09-25
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects will be recruited from the surgeons' private practices. These patients have already met the criteria for surgical intervention and have agreed to undergo the operative procedure and postoperative management.

Brief summary: This is a longitudinal, multi-center study to be conducted in at least five institutions from the private surgeon offices. These surgeons will collect data from X-rays, wound complications \\and hardware complications.


Eligibility criteria: Inclusion Criteria:

* Painful Hallux Limitus or Rigidus
* Painful Geriatric Hallux Valgus
* Failed prior 1st MTP joint arthroplasty (hemi-total)
* Arthritis of any etiology other than degenerative causes

Exclusion Criteria:

* Age less than 18 years
* Pregnant Females
* Active or prior infection at the target joint
* Immunocompromised patients
* Patients unwilling to sign informed consent
* Patient's unwilling to participate the in study protocol
* Subject with known sensitivity to titanium implants

Primary outcomes:
measure: Union Rates
timeFrame: 12 months
measure: Hardware Failures
timeFrame: 12 months
measure: Complications
timeFrame: 12 months
Secondary outcomes:
measure: Cost Data
timeFrame: 12 months
Other outcomes:
Locations:
city: Atlantis
country: United States
facility: JEM Research Institute
state: Florida
Study officials:
affiliation: JEM Research Institute
name: John Levin, DPM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02227186: Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York
Official title: Study of Effectiveness of a School-located Influenza Vaccination Program in Raising Influenza Vaccination Rates
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Childhood Influenza Vaccination
School-located Influenza Vaccination
Keywords: Influenza vaccination rates
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
First posted: 2014-08-28
Enrollment: 20461
Sex: ALL
Minimum age (years): 4
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Children in schools in which influenza vaccination clinics are held during school hours will have higher rates of influenza vaccination than children in control schools (no school-located clinics offered)


Eligibility criteria: Inclusion Criteria:

* Enrolled in participating, randomized school

Exclusion Criteria:

* None

Primary outcomes:
measure: Influenza vaccination status
timeFrame: Within one year
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester School of Medicine and Dentistry
state: New York
Study officials:
affiliation: University of Rochester
name: Peter Szilagyi, MPH, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yoo BK, Schaffer SJ, Humiston SG, Rand CM, Goldstein NPN, Albertin CS, Concannon C, Szilagyi PG. Cost effectiveness of school-located influenza vaccination programs for elementary and secondary school children. BMC Health Serv Res. 2019 Jun 24;19(1):407. doi: 10.1186/s12913-019-4228-5.
citation: Schaffer SJ, Rand CM, Humiston SG, Concannon C, Hightower AD, Albertin C, Szilagyi PG. Practical considerations in developing a successful school-located influenza vaccination (SLIV) program. Vaccine. 2019 Apr 10;37(16):2171-2173. doi: 10.1016/j.vaccine.2019.01.088. Epub 2019 Mar 13. No abstract available.
citation: Szilagyi PG, Schaffer S, Rand CM, Goldstein NPN, Younge M, Mendoza M, Albertin CS, Concannon C, Graupman E, Hightower AD, Yoo BK, Humiston SG. Text Message Reminders for Child Influenza Vaccination in the Setting of School-Located Influenza Vaccination: A Randomized Clinical Trial. Clin Pediatr (Phila). 2019 Apr;58(4):428-436. doi: 10.1177/0009922818821878. Epub 2019 Jan 2.
citation: Szilagyi PG, Schaffer S, Rand CM, Goldstein NPN, Vincelli P, Hightower AD, Younge M, Eagan A, Blumkin A, Albertin CS, DiBitetto K, Yoo BK, Humiston SG. School-located Influenza Vaccinations for Adolescents: A Randomized Controlled Trial. J Adolesc Health. 2018 Feb;62(2):157-163. doi: 10.1016/j.jadohealth.2017.09.021. Epub 2017 Dec 13.
citation: Szilagyi PG, Schaffer S, Rand CM, Vincelli P, Eagan A, Goldstein NP, Hightower AD, Younge M, Blumkin A, Albertin CS, Yoo BK, Humiston SG. School-Located Influenza Vaccinations: A Randomized Trial. Pediatrics. 2016 Nov;138(5):e20161746. doi: 10.1542/peds.2016-1746.
Clinical trial NCT00619086: Steroid Before Thyroidectomy
Official title: Does a Single Dose of Steroid Before Thyroidectomy Improve Postoperative Nausea, Pain and Vocal Function?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thyroid Surgery for Benign Disease
Keywords: thyroidectomy
dexamethasone
steroid
nausea
Lead sponsor: University of Bern
Sponsor class: OTHER
First posted: 2008-02-20
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: We evaluated the effects of giving a single dose of steroid before thyroid surgery in a single institutional, double-blinded, randomized controlled trial. Postoperative nausea, pain, and vocal function were significantly improved after steroid administration compared to controls.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing thyroid surgery for benign disease

Exclusion Criteria:

* Depression
* Chronic pain disorder
* Insulin dependent diabetes mellitus
* History of PONV
* Pregnancy
* Age \< 18 years
* Received antiemetic therapy within 48 hours

Primary outcomes:
measure: Nausea
timeFrame: 0-72 hours postoperative
Secondary outcomes:
measure: Pain, vocal function
timeFrame: 0-72 hours postoperative
Other outcomes:
Locations:
city: Bern
country: Switzerland
facility: Department of visceral- and transplant surgery
Study officials:
affiliation: Dept of visceral- and transplant surgery, University Hospital Bern
name: Stephan A. Vorburger, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Worni M, Schudel HH, Seifert E, Inglin R, Hagemann M, Vorburger SA, Candinas D. Randomized controlled trial on single dose steroid before thyroidectomy for benign disease to improve postoperative nausea, pain, and vocal function. Ann Surg. 2008 Dec;248(6):1060-6. doi: 10.1097/SLA.0b013e31818c709a.
Clinical trial NCT01101386: Study of Cyclodextrin (SBECD) and Voriconazole Blood Concentrations During Continuous Dialysis
Official title: Evaluation of Sulfobutylether-ß-cyclodextrin Sodium (SBECD) Accumulation and Voriconazole Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fungal Infection
Keywords: Voriconazole
SBECD
pharmacokinetics
Renal Failure
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2010-04-09
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospitalized patients

Brief summary: This study's primary objective is to determine if continuous renal replacement therapy (CRRT) can adequately remove the sulfobutylether-ß-cyclodextrin sodium (SBECD) vehicle from the blood so that intravenous voriconazole can be utilized in critically ill patients with renal dysfunction requiring dialysis. Secondarily, the pharmacokinetics of intravenous voriconazole and its metabolite (UK121-265) and adverse effects of SBECD accumulation will also be evaluated. The study hypothesis is that CRRT is effective at removing SBECD and allows patients to receive intravenous voriconazole without the concern of SBECD accumulation.


Eligibility criteria: Inclusion Criteria:

* Patients who are receiving continuous renal replacement therapy and are prescribed voriconazole therapy for the treatment or prophylaxis of a fungal infection.

Exclusion Criteria:

* Patients expected to be on CRRT for \< 5 days,
* Patients with Child-Pugh C cirrhosis, and
* Patients who are pregnant.

Primary outcomes:
measure: Determine SBECD plasma and effluent concentrations
timeFrame: Days 1-7
Secondary outcomes:
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: Days 1-30
measure: Determine Voriconazole and UK121-265 plasma and effluent concentrations
timeFrame: Days 1-7
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Hospital
state: Colorado
Study officials:
affiliation: Univesity of Colorado Anschutz Medical Campus
name: Ty H Kiser, PharmD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kiser TH, Fish DN, Aquilante CL, Rower JE, Wempe MF, MacLaren R, Teitelbaum I. Evaluation of sulfobutylether-beta-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care. 2015 Feb 3;19(1):32. doi: 10.1186/s13054-015-0753-8.
Clinical trial NCT00723086: Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer
Official title: An Extension Multicenter Phase II Open Label Non-comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Therapy, Prostatic Neoplasms
Keywords: docetaxel, prednisolone, drug combination
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2008-07-28
Enrollment: 16
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety of docetaxel administered every 3 weeks repeatedly for 11 and more cycles and in combination with daily prednisolone for metastatic hormone refractory prostate cancer.


Eligibility criteria: Inclusion Criteria:

Patients who completed the 10 cycles of docetaxel administrations in the preceding XRP6976J/2101 study and wish to continue docetaxel administrations,and who have no alternative therapy for hormone refractory prostate cancer according to the Investigator's judgment.

Exclusion Criteria:

* Continuation in the study would be detrimental to the patient's well-being
* Development of life-threatening and/or toxic conditions not manageable by symptomatic care, dose reduction, or delay of dosing
* Obvious disease progression (rising prostate specific antigen, any increase of ≥ 20 % in the sum of the measurable lesion in comparison to the nadir value, and progression in non-measurable lesion)
* Patients treated with anti-cancer treatment other than study therapy after completion of 10 cycles of study treatment in the XRP6976J/2101 study

Primary outcomes:
measure: Incidence rate of adverse events on each grade evaluated by National Cancer Institute Common Toxicity Criteria (Version 2.0)
timeFrame: First treatment up to 37 months
Secondary outcomes:
measure: No obvious disease progression
timeFrame: First treatment up to 37 months
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: ICD CSD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01568086: Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A
Official title: Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD03 Applied During AFFiRiS 005A
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Alzheimer's Disease
Lead sponsor: Affiris AG
Sponsor class: INDUSTRY
First posted: 2012-04-02
Enrollment: 16
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with mild to moderate Alzheimer's disease (MMSE 16 to 26)that have participated in AFF005A

Brief summary: This is a phase Ib follow-up study to evaluate long-term safety and tolerability of immunization with AFFITOPE AD03 applied during AFFiRiS 005A.


Eligibility criteria: Inclusion Criteria:

* Written informed consent signed and dated by the patient and the caregiver.
* Patients having participated in AFFiRiS 005A and received ≥1 vaccination with AFFITOPE AD03
* Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits and being available for the telephone phone calls

Exclusion Criteria:

* Patients having received no vaccination with AFFITOPE AD03
* History of questionable compliance to visit schedule; patients not expected to complete the clinical trial

Primary outcomes:
measure: Safety/Tolerability
timeFrame: 52 weeks
Secondary outcomes:
measure: Clinical Efficacy
timeFrame: 52 weeks
measure: Immunological
timeFrame: 52 weeks
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an derConfraternität-Privatklinik Josefstadt
city: Wien
country: Austria
facility: Medical University of Vienna, Department for Psychiatry and Psychotherapy
Study officials:
affiliation: Medical University of Vienna ,Department for Psychiatry and Psychotherapy
name: Siegfried Kasper, Prof.Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: Studienzentrum der PROSENEX,AmbulatoriumbetriebsgesmbH an derConfraternität-Privatklinik Josefstadt
name: Dieter Volc, Prim. Dr.
role: PRINCIPAL_INVESTIGATOR
References: